Shanghai Golden Leaf Med Tec Co., Ltd Secures Hundreds of Mns of CNY in Series C Round

Healthcare Author: Yan Zhang Dec 23, 2022 10:28 PM (GMT+8)

Hypertension interventional techniques, represented by RDN, have been a troika, along with lifestyle interventions and drug therapy, as a new approach to treat hypertension.


Shanghai Golden Leaf Med Tec Co., Ltd (Chinese: 魅丽纬叶), an interventional medical device developer, recently announced that it had completed a Series C financing round worth hundreds of millions of CNY. This funding round was jointly led by Jianxing Medical Fund (Chinese: 建兴医疗基金) and Fosun Health (Chinese: 复兴健康), with participation from NNFE Fund Management (Chinese: 新毅投资), Guangzhou Yiyao Investment (Chinese: 亿尧投资). Existing shareholder Hengxu Capital (Chinese: 恒旭资本) continued to invest. DAS Capital (Chinese: 点石资本) served as the financing advisor.

The funds raised will be used for the future commercialization of the renal denervation (RDN) product treating resistant hypertension, as well as the research and development, clinical trials, registration applications, and market expansion of the world's first endovascular denervation (EDN) product to treat diabetes mellitus type 2 (T2DM).

Founded in 2013, Shanghai Golden Leaf Med Tec Co., Ltd is a high-tech enterprise specializing in the research and development of interventional diagnosis and treatment devices for hypertension and cancer pain.

The RDN ablation system independently developed by the company won special approval for innovative medical devices in China in 2019, the CE certification in 2020, and the FDA granted "Breakthrough Device Designation" in 2021. The company has completed all patients' clinical trials and the clinical data review of the RDN product and will file the NMPA registration application soon, which is expected to become the first minimally invasive hypertension treatment device approved by NMPA.

Besides the RDN system, Shanghai Golden Leaf Med Tec Co., Ltd has developed the world's first EDN treatment approach to treat diabetes and verified the effectiveness and safety of EDN in small sample clinical trials.

Relevant enterprises include Bioheart (Chinese: 百心安), SyMap (Chinese: 信迈医疗) and Cryofocus Medtech (Chinese: 康沣生物).